Biogen Puts $750,000 Annual Price of Spinraza, A Rx That Treats Spinal Muscular Atrophy
Spinraza, which treats Spinal Muscular Atrophy (SMA), a rare genetic condition in children, costs $750,000 for the initial year of treatment. The Food and Drug Administration approved the first treatment for the condition two days before Christmas in 2016.

Across the country, similar stories are playing out as private insurers and already-squeezed state Medicaid programs wrestle with what, if any, limits to place on patients' access to break-the-bank drugs - weighing the needs of the ill against budget realities.

At the same time, policymakers and physicians increasingly demand to understand why drug manufacturers affix price tags that have risen to once unimaginable highs.

"It looks like a drug that works for a tragic condition that afflicts children and cripples and kills them. That's the good news, " Dr. Jerry Avorn, a professor of medicine at Harvard Medical School, says of Spinraza. But "how in the world did the price of $750,000 a year get chosen?"

Biogen, the maker of Spinraza, defends its price.

"We compared industry norms for other drugs in rare disease. We looked at the efficacy and safety profile of the drug itself," says Dr. Wildon Farwell, an epidemiologist and senior medical director of clinical development at Biogen.  

Please contact us with any questions.

Thank you, 
George Knox, CLU, ChFC
214.695.2904 (mobile)  214.443.1400 (office) |

Please Note: The information and materials herein are provided for general information purposes only and are not intended to constitute legal or other advice or opinions on any specific matters and are not intended to replace the advice of a qualified attorney, plan provider or other professional advisor. This information has been taken from sources which we believe to be reliable, but there is no guarantee as to its accuracy. In accordance with IRS Circular 230, this communication is not intended or written to be used, and cannot be used as or considered a 'covered opinion' or other written tax advice and should not be relied upon for any purpose other than its intended purpose.
The information provided herein is intended solely for the use of our clients and members. You may not display, reproduce, copy, modify, license, sell or disseminate in any manner any information included herein, without the express permission of the Publisher. Kindly read our Terms of Use and respect our Copyright.
© 2015 HR 360, Inc. - All rights reserved

Like us on Facebook    Follow us on Twitter